Back to Cagrilintide research
cagrilintide amylin agonist other 2024-03-19 ClinicalTrials

CagriSema Phase 3 Study Targets Type 2 Diabetes Management

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Background

Type 2 Diabetes is a chronic metabolic condition characterized by high blood sugar, often managed initially with diet and exercise. However, many individuals struggle to achieve adequate glycemic control with these methods alone, necessitating pharmacological interventions. This study addresses the need for more effective and comprehensive treatment options by evaluating a novel co-formulation designed to tackle multiple aspects of the disease.

Study Design

Population
Adults with Type 2 Diabetes who struggle to achieve adequate glycemic control with diet and exercise.
Intervention
CagriSema, a novel co-formulation designed to tackle multiple aspects of Type 2 Diabetes.
Outcome
The primary endpoint is not specified in the provided digest, but the study aims to evaluate more effective and comprehensive treatment options for Type 2 Diabetes.

cagrilintide semaglutide amylin agonist glp 1 agonist dose mentioned protocol relevant
Source: clinicaltrials:NCT06323174 · Ingested 2026-04-24 · Digest: gemini-2.5-flash